Trials / Completed
CompletedNCT03076164
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability and overall response rate of trametinib when given in combination with erlotinib in patients with Stage IV or recurrent lung adenocarcinoma that cannot be treated with curative intent.
Conditions
- Lung Adenocarcinoma
- Lung Cancer
- Lung Cancer Metastatic
- Lung Cancer Stage IV
- Recurrent Lung Adenocarcinoma
- Recurrent Lung Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trametinib | Trametinib 1.5mg once daily by mouth |
| DRUG | Erlotinib | Erlotinib 75mg once daily by mouth |
Timeline
- Start date
- 2017-03-01
- Primary completion
- 2020-12-18
- Completion
- 2020-12-18
- First posted
- 2017-03-10
- Last updated
- 2024-04-02
- Results posted
- 2022-02-08
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03076164. Inclusion in this directory is not an endorsement.